This Week In HIV Research


This Week in HIV Research: April 10, 2015

April 10, 2015

To beat HIV, we have to follow the science! However, that can be challenging since there's so much going on. To help you stay informed on interesting developments in HIV research and clinical news, here's our selection of highlights and under-the-radar developments from the past several days.

HHS Updates Antiretroviral Treatment Guidelines for Adults and Children

One of the biggest changes seen in this update was moving atazanavir (Reyataz) plus ritonavir (Norvir) and efavirenz/tenofovir/emtricitabine (Atripla) from "recommended" to "alternative" regimens, based on concerns over toxicities and a possible association with suicidality for efavirenz.


New and Improved Tenofovir Combination Submitted for FDA Approval

On April 7, Gilead submitted a new drug application to the U.S. Food and Drug Administration seeking approval for emtricitabine/tenofovir alafenamide, at two fixed doses, for the treatment of HIV. The combination includes the improved version of tenofovir, tenofovir alafenamide (TAF), and would effectively replace emtricitabine/tenofovir dipivoxil fumarate, sold under the brand name Truvada.

Broadly Neutralizing Antibody Suppresses HIV in Clinical Trial

Richard Jefferys of Treatment Action Group breaks down a new study that confirms the potential of broadly neutralizing antibodies (bNAbs) against HIV in humans, results that are consistent with data seen in studies with humanized mice and macaques. Broadly neutralizing antibodies are one of the keys to developing a successful HIV vaccine, given their unique ability to protect against many different antigens (hence "broadly neutralizing").

Souped-Up IL-15 Sparks Natural Killer Cell Activity Against HIV

In addition to broadly neutralizing antibodies, HIV vaccine research focuses on other components of the immune system, including natural killer (NK) cells and CD8 T cells, which may be elicited by the cytokine interleukin 15 (IL-15). A new study found an association between IL-15 and delayed viral load rebound after treatment interruption.

Women in PrEP Trial Feared They Would Have to Leave Study if They Reported Low Adherence

New data suggest that social desirability bias may have been the reason why participants exaggerated their adherence to pre-exposure prophylaxis (PrEP) in the FEM-PrEP study, which was stopped early in 2011.

Cost-Effectiveness of Community-Based Strategies for HIV

This analysis in The Lancet HIV further emphasizes how cost-effective antiretroviral therapy is when individuals are tested, diagnosed and linked to care.

Is there a development this week in HIV research that you think we missed? Send us a tip!

Warren Tong is the senior science editor for and

Follow Warren on Twitter: @WarrenAtTheBody.

Copyright © 2015 Remedy Health Media, LLC. All rights reserved.

This article was provided by TheBodyPRO.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.